Chengdu Kanghua Biological Products Co., Ltd.

Shenzhen Stock Exchange 300841.SZ

Chengdu Kanghua Biological Products Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.05

Chengdu Kanghua Biological Products Co., Ltd. Debt to Equity Ratio is 0.05 for the year ending December 31, 2023, a 32.25% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Chengdu Kanghua Biological Products Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.04, a 12,081.65% change year over year.
Chengdu Kanghua Biological Products Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.00, a -71.55% change year over year.
Chengdu Kanghua Biological Products Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.00, a -93.19% change year over year.
Chengdu Kanghua Biological Products Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.02, a -66.32% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shenzhen Stock Exchange: 300841.SZ

Chengdu Kanghua Biological Products Co., Ltd.

CEO	Mr. Wennian Wu
IPO Date	June 16, 2020
Location	China
Headquarters	No. 182, Beijing Road
Employees	672
Sector	Healthcare
Industries Vaccines Biotechnology

Description

Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials; and human H5N1 influenza vaccine that completed pre-clinical studies. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.

Key trends

Past 5 years